Suppr超能文献

澳大利亚西部孤独症个体(21 岁及以下)使用精神类药物:初步调查。

The use of psychotropic medications in autistic individuals (21 years and younger) in Western Australia: A preliminary investigation.

机构信息

Curtin University, Australia.

Perth Children's Hospital, Australia.

出版信息

Autism. 2024 Aug;28(8):2002-2013. doi: 10.1177/13623613231226099. Epub 2024 Feb 22.

Abstract

Prescriptions and use of medications to treat mental health conditions in young autistic populations are inconsistent worldwide. This makes it hard to compare findings from international studies to the Australian autistic population, where there are limited relevant studies. Apart from risperidone, there are no other medications specified for direct use in autistic persons. This study aims to gain initial broad understanding of the use of medications, commonly prescribed for mental health conditions, specifically by autistics under the age of 21 years. We analysed data that were previously collected as part of the Western Australian Autism Biological Registry between 2011 and 2015 which amounted to 239 surveys completed on young persons with diagnosed autism. The questionnaires included information on co-occurring conditions, current or previous use of medications and reasons for use of the medications. Only one-quarter of the participants in this study reported using at least one mental health-related medication in their lifetime. The most reported medications were stimulants, antidepressants and antiepileptics. The reasons for using medication included managing attention deficit hyperactivity disorder, challenging behaviours, seizures, sleep difficulties and symptoms of anxiety and depression. The number of individuals reporting medication use in this study was lower compared to other developed countries. Nevertheless, these medications should be monitored due to limited understanding of their use to manage co-occurring symptoms in young autistic persons. The findings highlight the importance of ongoing research to better understand mental health-related medications and inform best practice.

摘要

治疗自闭症儿童精神健康状况的处方和药物使用在全球范围内并不一致。这使得很难将国际研究结果与澳大利亚自闭症群体进行比较,而澳大利亚自闭症群体相关研究有限。除了利培酮之外,没有其他药物被指定可直接用于自闭症患者。本研究旨在初步广泛了解针对精神健康状况的药物使用情况,特别是 21 岁以下自闭症患者的药物使用情况。我们分析了 2011 年至 2015 年期间作为西澳大利亚自闭症生物登记处一部分收集的数据,该数据共包括 239 份对已确诊自闭症的年轻人进行的调查。调查问卷包括共病情况、当前或以前使用药物以及使用药物的原因等信息。在这项研究中,只有四分之一的参与者报告在他们的一生中至少使用过一种与精神健康相关的药物。报告使用最多的药物是兴奋剂、抗抑郁药和抗癫痫药。使用药物的原因包括治疗注意力缺陷多动障碍、行为问题、癫痫发作、睡眠困难以及焦虑和抑郁症状。与其他发达国家相比,本研究报告药物使用者的人数较少。然而,由于对这些药物用于管理年轻自闭症患者共病症状的使用了解有限,因此仍应监测这些药物的使用情况。研究结果强调了持续开展研究以更好地了解与精神健康相关的药物并为最佳实践提供信息的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9aea/11301957/3dcd4b4db519/10.1177_13623613231226099-fig1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验